Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Short-term Investments (2016 - 2025)

Sangamo Therapeutics (SGMO) has 15 years of Short-term Investments data on record, last reported at $912000.0 in Q3 2025.

  • For Q3 2025, Short-term Investments changed N/A year-over-year to $912000.0; the TTM value through Sep 2025 reached $912000.0, changed N/A, while the annual FY2021 figure was $197.7 million, 61.25% down from the prior year.
  • Short-term Investments reached $912000.0 in Q3 2025 per SGMO's latest filing, down from $75.6 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $464.1 million in Q1 2021 and bottomed at $912000.0 in Q3 2025.
  • Average Short-term Investments over 4 years is $203.5 million, with a median of $197.8 million recorded in 2021.
  • Peak YoY movement for Short-term Investments: skyrocketed 82.25% in 2021, then tumbled 65.48% in 2023.
  • A 4-year view of Short-term Investments shows it stood at $197.7 million in 2021, then increased by 10.79% to $219.0 million in 2022, then crashed by 65.48% to $75.6 million in 2023, then crashed by 98.79% to $912000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Short-term Investments were $912000.0 in Q3 2025, $75.6 million in Q3 2023, and $76.3 million in Q2 2023.